Halozyme Therapeutics, Inc. (HALO) is a publicly traded Healthcare sector company. As of November 3, 2026, HALO trades at $129.45 with a market cap of $14.86B and a P/E ratio of 30.86. HALO moved -1.51% today. Year to date, HALO is +83.34%; over the trailing twelve months it is +97.74%. Its 52-week range spans $47.50 to $134.00. Analyst consensus is buy with an average price target of $105.86. Rallies surfaces HALO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
7 analysts cover HALO: 0 strong buy, 5 buy, 2 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $105.86.
| Metric | Value |
|---|---|
| Price | $129.45 |
| Market Cap | $14.86B |
| P/E Ratio | 30.86 |
| EPS | $3.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $134.00 |
| 52-Week Low | $47.50 |
| Volume | 2.95M |
| Avg Volume | 0 |
| Revenue (TTM) | $1.66B |
| Net Income | $413.60M |
| Gross Margin | 82.42% |
7 analysts cover HALO: 0 strong buy, 5 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $105.86.